查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1485079

神經生物標記物免疫測定市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、疾病、應用、地區和競爭細分，2019-2029F

Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Disease, By Application, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 184 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球神經生物標記免疫測定市場估值為6.2422 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為11.45%。測定技術為中心的產業用於檢測和測量各種生物樣本中的神經生物標記。神經生物標記是特定的分子或物質，可以深入了解神經系統疾病和病症（例如阿茲海默症、帕金森氏症、多發性硬化症和中風）的存在、進展和嚴重程度。該市場的成長是由全球神經系統疾病日益流行以及對準確和早期診斷的迫切需求所推動的。免疫測定技術在檢測微量生物標記方面具有高靈敏度和特異性，使臨床醫生能夠在早期階段識別潛在的神經系統疾病，此時干預可能更有效。

市場概況
預測期 2025-2029
2023 年市場規模 6.2422億美元
2029 年市場規模 11.9176億美元
2024-2029 年複合年成長率 11.45%
成長最快的細分市場 試劑
最大的市場 北美洲

免疫測定技術的進步，包括酵素連結免疫吸附測定 (ELISA) 和多重免疫測定，提高了生物標記檢測的精確度和效率。此外，對個人化醫療日益成長的興趣導致了對標靶治療的需求，這使得準確的生物標記識別對於客製化治療至關重要。該市場受到旨在識別新型神經生物標記和提高免疫分析平台性能的研發工作的影響。免疫測定過程中自動化和數位化的整合提高了工作流程效率和資料分析。

該市場面臨的挑戰包括神經系統疾病的複雜性、某些疾病的特定生物標記的識別以及確保結果的可重複性和可靠性。監管考慮和強大驗證的需求也會影響市場動態。總之，神經生物標記市場的全球免疫分析在改善神經系統疾病的診斷和管理方面發揮關鍵作用。免疫分析技術的進步和對個人化醫療的日益重視正在推動其成長，同時解決與生物標記驗證和可重複性相關的挑戰對於進一步擴大市場仍然至關重要。

主要市場促進因素

神經系統疾病盛行率上升

人口老化加劇

免疫分析技術的進步

主要市場挑戰

神經系統疾病的複雜性

缺乏充分錶徵的生物標記

主要市場趨勢

合作與夥伴關係

細分市場洞察

產品洞察

疾病洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球神經生物標記免疫測定市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依產品（儀器、試劑、服務）
    • 依疾病分類（阿茲海默症、帕金森氏症、多發性硬化症、其他）
    • 依應用（體外診斷、研究）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司分類 (2023)
  • 市場地圖
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按地區

第 6 章：北美神經生物標記免疫測定市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲神經生物標記免疫測定市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區神經生物標記免疫分析市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲

第 9 章：南美洲神經生物標記免疫測定市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲神經生物標記免疫分析市場前景

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按產品分類
    • 按疾病分類
    • 按申請
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 併購
  • 產品開發
  • 最近的發展

第13章：波特的分析

第 14 章：PESTEL 分析

第15章：競爭格局

  • QIAGEN NV
  • Abbott Laboratories Inc.
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories, Inc.
  • Sysmex Corporation
  • F. Hoffmann La-Roche Ltd.
  • Nimble Therapeutics Inc.

第 16 章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 20976

Global Immunoassay for Neurological Biomarkers Market was valued at USD 624.22 Million in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 11.45% through 2029. The Global Immunoassay for Neurological Biomarkers Market pertains to the industry centered around immunoassay technologies used for detecting and measuring neurological biomarkers in various biological samples. Neurological biomarkers are specific molecules or substances that provide insights into the presence, progression, and severity of neurological disorders and conditions such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke. This market's growth is driven by the increasing prevalence of neurological disorders worldwide and the pressing need for accurate and early diagnosis. Immunoassay techniques offer high sensitivity and specificity in detecting even trace amounts of biomarkers, enabling clinicians to identify potential neurological conditions at an earlier stage, when intervention might be more effective.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 624.22 Million
Market Size 2029USD 1,191.76 Million
CAGR 2024-202911.45%
Fastest Growing SegmentReagents
Largest MarketNorth America

Advancements in immunoassay technologies, including enzyme-linked immunosorbent assays (ELISA) and multiplex immunoassays, have improved the precision and efficiency of biomarker detection. Additionally, the growing interest in personalized medicine has led to a demand for targeted treatments, making accurate biomarker identification crucial for tailoring therapies. The market is influenced by research and development efforts aimed at identifying novel neurological biomarkers and improving the performance of immunoassay platforms. The integration of automation and digitalization in immunoassay processes enhances workflow efficiency and data analysis.

Challenges in this market include the complexity of neurological conditions, the identification of specific biomarkers for certain disorders, and ensuring the reproducibility and reliability of results. Regulatory considerations and the need for robust validation also impact market dynamics. In conclusion, the Global Immunoassay for Neurological Biomarkers Market plays a pivotal role in improving the diagnosis and management of neurological disorders. Advancements in immunoassay technologies and a growing emphasis on personalized medicine are driving its growth, while addressing challenges related to biomarker validation and reproducibility remains essential for further market expansion.

Key Market Drivers

Rising Prevalence of Neurological Disorders

The rising prevalence of neurological disorders is a significant driver in the Global Immunoassay for Neurological Biomarkers Market. Neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and stroke, are becoming increasingly prevalent across the globe. Factors such as aging populations, changing lifestyles, and improved diagnostics contribute to this trend. As the number of individuals affected by these disorders grows, there is a pressing need for accurate and early diagnostic methods to facilitate timely intervention and management. Immunoassay technologies offer a promising solution by enabling the identification and measurement of specific biomarkers associated with neurological conditions. These biomarkers can indicate disease progression, severity, and response to treatment. The immunoassay-based detection of neurological biomarkers allows healthcare professionals to identify potential neurological disorders at earlier stages, enabling the implementation of appropriate therapeutic strategies.

The use of immunoassays supports research efforts to uncover novel biomarkers that could provide insights into disease mechanisms and aid in the development of targeted therapies. The increasing prevalence of neurological disorders underscores the importance of continuous research and development in immunoassay technologies. These advancements not only improve the accuracy and sensitivity of biomarker detection but also contribute to the expansion of the Global Immunoassay for Neurological Biomarkers Market, offering healthcare providers valuable tools to combat the growing burden of neurological diseases.

Growing Aging Population

The growing aging population is a significant driver shaping the Global Immunoassay for Neurological Biomarkers Market. With a substantial increase in the number of elderly individuals globally, the prevalence of age-related neurological disorders is on the rise. This demographic shift has far-reaching implications for healthcare, particularly in the diagnosis, treatment, and management of neurological conditions. As people age, their risk of developing neurological disorders such as Alzheimer's disease, Parkinson's disease, and stroke significantly increases. These conditions can have profound impacts on individuals' quality of life and pose significant challenges for healthcare systems. Immunoassay technologies play a crucial role in addressing these challenges. The accurate and early diagnosis of neurological disorders becomes paramount in an aging population.

Immunoassay-based detection of specific biomarkers associated with these conditions provides a non-invasive and efficient means of identifying early signs and tracking disease progression. This early intervention can lead to improved outcomes and better management strategies for patients. Furthermore, the demand for personalized medicine is amplified in an aging population, where individuals may have unique biomarker profiles and responses to treatment. Immunoassays enable healthcare providers to tailor therapies based on these individual variations, ensuring that interventions are more effective and suitable for each patient. In the Global Immunoassay for Neurological Biomarkers Market, the growing aging population emphasizes the importance of continued research and development efforts to identify novel biomarkers, enhance immunoassay technologies, and improve the precision of neurological disorder diagnoses. By addressing the specific needs of an aging demographic, immunoassay technologies contribute to enhanced patient care, better disease management, and the advancement of neurology as a whole.

Advancements in Immunoassay Technologies

Advancements in immunoassay technologies are playing a pivotal role in shaping the Global Immunoassay for Neurological Biomarkers Market. These technological innovations are revolutionizing the field of diagnostics, especially in the context of neurological disorders. Recent advancements include the development of multiplex immunoassays, which allow the simultaneous detection and measurement of multiple biomarkers in a single sample. This not only saves time but also provides a comprehensive understanding of the patient's condition, aiding in accurate diagnoses and personalized treatment plans. Furthermore, digital immunoassays utilize digital platforms to enhance sensitivity and precision, enabling the quantification of biomarkers at lower concentrations. This is particularly valuable in detecting subtle neurological biomarker changes, especially in the early stages of diseases.

Automated immunoassay systems are streamlining workflows, reducing human error, and improving efficiency in laboratories. These systems offer high-throughput capabilities, making them suitable for processing large volumes of patient samples in a shorter time frame. Integration with data analytics and artificial intelligence (AI) is another notable advancement. AI algorithms can analyze complex biomarker patterns, aiding clinicians in making informed decisions and improving the accuracy of diagnoses. These advancements collectively enhance the reliability, efficiency, and accuracy of immunoassay-based neurological biomarker detection. They empower healthcare professionals to detect neurological disorders earlier, monitor disease progression more effectively, and tailor treatments to individual patients, ultimately improving patient outcomes and advancing the capabilities of neurology diagnostics and research.

Key Market Challenges

Complexity of Neurological Disorders

The complexity of neurological disorders poses a significant challenge in the Global Immunoassay for Neurological Biomarkers Market. Neurological disorders encompass a wide spectrum of conditions, each characterized by intricate and multifaceted pathophysiological mechanisms. This complexity translates into a diverse range of potential biomarkers that can reflect different aspects of disease progression, severity, and response to treatment. The heterogeneity of neurological disorders means that identifying specific biomarkers that accurately represent disease states is a complex task. Researchers need to consider the interplay of various molecular pathways, cellular interactions, and genetic factors that contribute to these disorders. The overlap of symptoms and the lack of unique biomarkers for certain conditions further complicate the biomarker discovery process. The complexity of neurological disorders also presents challenges in the validation and standardization of biomarkers.

Variability in patient populations, disease stages, and underlying genetics can lead to inconsistent biomarker profiles. Ensuring that identified biomarkers are reliable indicators of disease presence or progression across diverse patient groups is a formidable task. Overcoming the complexity of neurological disorders requires comprehensive and interdisciplinary research efforts. Collaborations between neuroscientists, immunologists, geneticists, and clinicians are essential for gaining a deeper understanding of the underlying biology and identifying robust biomarkers. Advanced technologies, such as multi-omics approaches and artificial intelligence, play a crucial role in deciphering the intricate molecular signatures associated with neurological conditions. Ultimately, addressing the complexity of these disorders is vital for developing accurate and effective immunoassay-based diagnostic tools that can aid in early detection and personalized treatment approaches.

Lack of Well-Characterized Biomarkers

The lack of well-characterized biomarkers presents a notable challenge in the Global Immunoassay for Neurological Biomarkers Market. Biomarkers are specific molecules or indicators that provide insights into the presence, progression, and severity of neurological disorders. In many cases, the field of neurology still lacks a comprehensive understanding of which biomarkers reliably represent specific diseases. Neurological disorders are inherently complex, with intricate underlying mechanisms that vary among individuals. This complexity makes it difficult to identify biomarkers that accurately reflect disease states and progression. The absence of well-characterized biomarkers stems from the challenges of defining specific molecules that are consistently associated with particular neurological conditions. The lack of standardized biomarkers hampers the development of reliable immunoassay-based diagnostic tests. Inconsistent or poorly validated biomarkers can lead to inaccurate diagnoses and misinformed treatment decisions. This challenge also affects the comparability of research findings across studies, hindering the progress of biomarker discovery and validation.

Addressing the lack of well-characterized biomarkers requires collaborative efforts between researchers, clinicians, and diagnostic companies. Robust clinical studies involving large and diverse patient populations are crucial for identifying biomarkers with high specificity and sensitivity. Advances in omics technologies and high-throughput profiling methods are aiding in the search for potential biomarkers, although validation and standardization remain key challenges. In conclusion, overcoming the lack of well-characterized biomarkers is essential for advancing the Global Immunoassay for Neurological Biomarkers Market. Rigorous research, comprehensive clinical studies, and interdisciplinary collaborations are necessary to identify and validate biomarkers that accurately reflect the intricate nature of neurological disorders, ultimately enhancing diagnostic accuracy and patient care.

Key Market Trends

Collaborations and Partnerships

Collaborations and partnerships are playing a crucial role in shaping the Global Immunoassay for Neurological Biomarkers Market. In this context, collaborations refer to the cooperation between diverse stakeholders, including research institutions, diagnostic companies, pharmaceutical manufacturers, and healthcare providers. These collaborations facilitate the sharing of knowledge, expertise, and resources, ultimately accelerating progress in biomarker research and the development of immunoassay-based diagnostic solutions. Partnerships and collaborations offer several benefits in the field of neurological biomarkers. They leverage the collective strengths of different organizations, enabling access to specialized skills, advanced technologies, and extensive patient data. Academic research institutions contribute to the discovery and validation of novel biomarkers, while diagnostic companies bring expertise in assay development and commercialization.

Pharmaceutical manufacturers play a role in translating biomarker research into actionable insights for drug development and treatment strategies. Healthcare providers contribute clinical expertise and real-world patient data, ensuring that developed diagnostic tools are clinically relevant and effective in practice. Collaborations also address the complexity of neurological disorders, which require multidisciplinary approaches. Neuroscientists, immunologists, geneticists, clinicians, and engineers working together can provide comprehensive insights into disease mechanisms and biomarker profiles. In the context of the Global Immunoassay for Neurological Biomarkers Market, collaborations and partnerships expedite the translation of research findings into practical diagnostic solutions. By fostering an environment of open communication and shared goals, these collaborative efforts enhance diagnostic accuracy, contribute to personalized treatment approaches, and ultimately benefit patients by improving neurological disorder management.

Segmental Insights

Product Insights

Based on product, reagents emerged as the fastest growing segment in the Global Immunoassay for Neurological Biomarkers Market during the forecast period. Continual progress in neuroscience research has uncovered new biomarkers linked to diverse neurological conditions. Immunoassays offer a dependable and precise means of measuring these biomarkers in biological specimens. The evolution of high-throughput immunoassay platforms, boasting enhanced sensitivity, specificity, and multiplexing capabilities, has broadened the scope of immunoassay applications in neurological biomarker investigations. Initiatives such as awareness campaigns and screening programs targeting the early detection of neurological disorders are bolstering the demand for immunoassays within this market segment.

Disease Insights

Based on disease, Alzheimer's Disease emerged as the dominating segment in the Global Immunoassay for Neurological Biomarkers Market during the forecast period. Alzheimer's disease stands out as the most prevalent type of dementia worldwide, constituting a significant proportion of neurological disorders. This prevalence underscores the imperative for developing and employing biomarkers to detect and track the disease's progression at its early stages. There is considerable research directed towards comprehending the pathophysiology of Alzheimer's and pinpointing new biomarkers capable of signaling the disease's trajectory. Immunoassays emerge as pivotal tools offering precise and sensitive means of measuring these biomarkers, thus asserting their prominence in the market. In regions with robust healthcare infrastructures and established diagnostic facilities, there's a tendency to adopt cutting-edge diagnostic technologies like immunoassays for the detection and monitoring of Alzheimer's disease.

Regional Insights

Based on region, North America dominated the Global Immunoassay for Neurological Biomarkers Market in 2023. This dominance can be attributed to the rising incidence of chronic diseases, encompassing breast cancer, cardiology, and neurological disorders, within the region. The demand for immunoassays is particularly driven by the need for accurate diagnosis and monitoring of neurological conditions, given their significant impact on public health and healthcare expenditure. North America's advanced healthcare infrastructure, coupled with substantial investments in research and development, further propels the adoption of immunoassays for neurological biomarkers. As the prevalence of neurological disorders continues to rise globally, North America remains at the forefront of innovation and market growth in the immunoassay sector, shaping the landscape of neurological diagnostics and therapeutics.

Key Market Players

QIAGEN NV

Abbott Laboratories Inc.

Merck & Co., Inc.

Johnson & Johnson Services, Inc.

Thermo Fisher Scientific, Inc.

Bio-Rad Laboratories, Inc.

Sysmex Corporation

F. Hoffmann La-Roche Ltd.

Nimble Therapeutics Inc.

Report Scope:

In this report, the Global Immunoassay for Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Immunoassay for Neurological Biomarkers Market, By Product:

    Instruments Reagents Services

Immunoassay for Neurological Biomarkers Market, By Disease:

    Alzheimer's Disease Parkinson's Disease Multiple Sclerosis Others

Immunoassay for Neurological Biomarkers Market, By Application:

    In Vitro Diagnostics Research

Immunoassay for Neurological Biomarkers Market, By Region:

    North America

United States

Canada

Mexico

    Europe

France

United Kingdom

Italy

Germany

Spain

    Asia Pacific

China

India

Japan

Australia

South Korea

    South America

Brazil

Argentina

Colombia

    Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Immunoassay for Neurological Biomarkers Market.

Available Customizations:

Global Immunoassay for Neurological Biomarkers Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Immunoassay for Neurological Biomarkers Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Reagents, Services)
    • 5.2.2. By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others)
    • 5.2.3. By Application (In Vitro Diagnostics, Research)
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2023)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Disease
    • 5.3.3. By Application
    • 5.3.4. By Region

6. North America Immunoassay for Neurological Biomarkers Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Disease
    • 6.2.3. By Application
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Disease
        • 6.3.1.2.3. By Application
    • 6.3.2. Canada Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Disease
        • 6.3.2.2.3. By Application
    • 6.3.3. Mexico Immunoassay for Neurological Biomarkers Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Disease
        • 6.3.3.2.3. By Application

7. Europe Immunoassay for Neurological Biomarkers Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Disease
    • 7.2.3. By Application
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Disease
        • 7.3.1.2.3. By Application
    • 7.3.2. France Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Disease
        • 7.3.2.2.3. By Application
    • 7.3.3. United Kingdom Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Disease
        • 7.3.3.2.3. By Application
    • 7.3.4. Italy Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Disease
        • 7.3.4.2.3. By Application
    • 7.3.5. Spain Immunoassay for Neurological Biomarkers Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Disease
        • 7.3.5.2.3. By Application

8. Asia Pacific Immunoassay for Neurological Biomarkers Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Disease
    • 8.2.3. By Application
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Disease
        • 8.3.1.2.3. By Application
    • 8.3.2. Japan Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Disease
        • 8.3.2.2.3. By Application
    • 8.3.3. India Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Disease
        • 8.3.3.2.3. By Application
    • 8.3.4. South Korea Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Disease
        • 8.3.4.2.3. By Application
    • 8.3.5. Australia Immunoassay for Neurological Biomarkers Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Disease
        • 8.3.5.2.3. By Application

9. South America Immunoassay for Neurological Biomarkers Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Disease
    • 9.2.3. By Application
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Disease
        • 9.3.1.2.3. By Application
    • 9.3.2. Argentina Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Disease
        • 9.3.2.2.3. By Application
    • 9.3.3. Colombia Immunoassay for Neurological Biomarkers Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Disease
        • 9.3.3.2.3. By Application

10. Middle East and Africa Immunoassay for Neurological Biomarkers Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Disease
    • 10.2.3. By Application
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Disease
        • 10.3.1.2.3. By Application
    • 10.3.2. Saudi Arabia Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Disease
        • 10.3.2.2.3. By Application
    • 10.3.3. UAE Immunoassay for Neurological Biomarkers Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Disease
        • 10.3.3.2.3. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Merck & Co., Inc.
  • 15.4. Johnson & Johnson Services, Inc.
  • 15.5. Thermo Fisher Scientific, Inc.
  • 15.6. Bio-Rad Laboratories, Inc.
  • 15.7. Sysmex Corporation
  • 15.8. F. Hoffmann La-Roche Ltd.
  • 15.9. Nimble Therapeutics Inc.

16. Strategic Recommendations

17. About Us & Disclaimer